Thomas Proctor, et al v. Safeway, Inc.

  1. July 05, 2023

    FCA Defense Bar Tries Flipping Script On High Court Ruling

    After the U.S. Supreme Court recently fortified barriers to escaping False Claims Act suits, defense counsel have started trying to turn the stumbling blocks into stepping stones, insisting the justices actually made matters harder for FCA plaintiffs alleging fraud and retaliation.

  2. June 12, 2023

    DOJ Sees Far-Reaching Victory In High Court's FCA Ruling

    The U.S. Supreme Court's ruling that faulty yet reasonable compliance views can trigger False Claims Act liability is undermining defense bar positions in wide-ranging contexts, including a new circuit split over FCA cases involving kickbacks, according to the U.S. Department of Justice.

  3. August 09, 2022

    7th Circ. View Of FCA Intent Is 'Deeply Flawed,' Justices Told

    An Illinois pharmacist wants the U.S. Supreme Court to review a refusal by a split Seventh Circuit to revive his False Claims Act suit against Safeway, raising an issue about how to determine a defendant's knowledge of wrongdoing in an FCA case.

  4. July 08, 2022

    Top Gov't Contract Cases In 2022: Midyear Report

    Courts and administrative bodies have issued several important decisions affecting government contractors this year, for example touching on the government's authority to respond to the COVID-19 pandemic and creating splits between the U.S. Government Accountability Office and Court of Federal Claims.

  5. April 05, 2022

    7th Circ. Won't Revive False Claims Act Suit Against Safeway

    A split Seventh Circuit panel on Tuesday refused to revive an Illinois pharmacist's False Claims Act suit against Safeway, agreeing with a lower court's finding that the supermarket chain's drug pricing practices passed muster.

  6. February 10, 2021

    7th Circ. Asked To Revive Safeway Drug Price Suit

    An Illinois pharmacist is asking the Seventh Circuit to reinstate a False Claims Act suit against supermarket chain Safeway, saying there's ample evidence the company knowingly overbilled federal and state health care programs for prescription drugs.